Engineered immune cells take on liver cancer in early trial
NCT ID NCT03132792
First seen Jun 23, 2026 · Last updated Jun 23, 2026
Summary
This early-phase trial tested a new approach for advanced liver cancer that has not responded to standard treatments. Researchers took participants' own immune cells, modified them in a lab to target a protein called AFP found on cancer cells, and infused them back after a short course of chemotherapy. The main goals were to check safety and find the right dose, with 39 adults enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
-
Centre Eugène Marquis
Rennes, France
-
Fred Hutchinson Cancer Research Centre
Seattle, Washington, 98109, United States
-
Guy's Hospital
London, SE1 9RT, United Kingdom
-
Institute Gustave Roussy
Villejuif, France
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Clinical Trial Referral Office
Rochester, Minnesota, 55905, United States
-
NIHR UCLH Clinical Research
London, W1T7HA, United Kingdom
-
Paoli Calmettes Institute
Marseille, France
-
SCCA Immunotherapy Trials Intake
Seattle, Washington, 98109, United States
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
UCLA
Los Angeles, California, 90095, United States
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University Hospital of Barcelona
Barcelona, 08036, Spain
-
University Hospital of Navarra
Pamplona, 31008, Spain
-
University of Maryland, Greenebaum Cancer Center
Baltimore, Maryland, 21201, United States
-
University of Miami
Miami, Florida, 33136, United States
-
Washington University - School of Medicine
St Louis, Missouri, 63110, United States
-
Winship Cancer Institute - Emory University
Atlanta, Georgia, 30322, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
genetically modified T cells (AFPᶜ³³²T cells)
What this could lead to
If it works, this could point toward a new treatment option for advanced liver cancer that has not responded to other therapies.
What could go wrong
This is an early phase 1 trial with only 39 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects from the chemotherapy and the modified T cells.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.